News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

CaridianBCT, Inc. Receives FDA 510(k) Clearance on Latest Version of Trima Accel Automated Blood Collection System

3/3/2010 6:36:55 AM

LAKEWOOD, Colo.--(BUSINESS WIRE)--CaridianBCT, a leading global provider of technology, products and services in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies announced it has received 510(k) clearance for the Trima Accel® Automated Blood Collection System Version 6.0—providing increased efficiencies and streamlined operations to blood centers.

“This is a major product enhancement for our flagship automated blood collection system,” said David Perez, president and chief executive officer of CaridianBCT. “The Trima Accel Version 6.0 demonstrates our ongoing commitment to provide customers with a flexible platform, providing the most blood component collection options to maximize a blood center’s operations and realize greater productivity—whether in fixed or mobile sites.”

The latest version of the Trima Accel system includes the Auto Red Blood Cell (RBC) procedure, allowing for the collection of a ready-to-transfuse leukoreduced red blood cell product from donors and eliminating the requirement for post-procedure leukoreduction and addition of storage solution.

“The Trima Accel V6.0 Auto RBC procedure brings a host of improvements and additional ease-of-use to blood centers and helps them meet the changing blood supply needs of hospitals,” said Bob Cole, senior vice president of CaridianBCT’s Automated Collections business area. “By increasing efficiencies through streamlining operations and reducing the opportunities for error, the Auto RBC procedure will benefit blood centers.”

After receiving 510(k) clearance on February 16, 2010, CaridianBCT plans to launch Trima Accel system V6.0 in multiple markets around the world over the next several months.

About CaridianBCT:

CaridianBCT is the leading global provider of innovative technologies and services specializing in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies. The company serves patients through its commitment “For Better Blood and Better Lives” by developing and commercializing products that serve global customers in the blood banking, therapeutic apheresis and transfusion medicine industries. For more information, visit


CaridianBCT Tarra Ryerson, +1 303-246-3868 (Mobile) Manager of Global Corporate Communications

Read at

comments powered by Disqus